Consider the Whole Patient When Choosing Treatment, Says Dr. Marc Bonaca

Patients often have comorbidities that make it important to consider them holistically and not bucket them into one disease state, and the findings on rivaroxaban show broad benefits and a favorable risk-benefit profile, said Marc Bonaca, executive director of CPC Clinical Research and CPC Community Health and director of vascular research, associate professor of medicine, and the William R. Hiatt Endowed Chair in Cardiovascular Research at the University of Colorado School of Medicine.